Open AccessIs the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry
Author(s) -
B. Farisoğulları,
G. K. Yardimci,
Alper Sarı,
Emre Bılgın,
Ertuğrul Çağrı Bölek,
E. Durán,
Levent Kılıç,
Ali Akdoğan,
Ömer Karadağ,
Şule Apraş Bilgen,
Ali İhsan Ertenli,
Sedat Kiraz,
Umut Kalyoncu
Publication year - 2022
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/uxcofr
Subject(s) - medicine , sacroiliitis , infliximab , ankylosing spondylitis , erythrocyte sedimentation rate , inflammatory bowel disease , psoriatic arthritis , spondylitis , ulcerative colitis , rheumatology , gastroenterology , adalimumab , arthritis , disease